Bayer’s preferred shares (BAYN.DE) demonstrated modest resilience in Thursday’s trading session, closing at $8.08 with a slight gain of 0.12%. This minor uptick, however, masks the substantial challenges confronting the life sciences conglomerate as it contends with mounting legal pressures and revised financial projections.
Operational Performance Defies Challenges
Despite facing significant legal headwinds, Bayer unveiled surprisingly robust operational results for the second quarter of 2025. The company reported adjusted earnings per share surged by 31% to reach €1.23, propelled by improved financial results and reduced tax burdens. Group revenue totaled €10.7 billion, representing a currency-adjusted increase of 1% despite reporting a 4% decline due to substantial adverse currency effects.
The company’s twelve-month trailing earnings per share through June 2025 stood at -$0.97, highlighting the ongoing difficulties in maintaining consistent profitability across its diverse business segments while managing persistent legal pressures.
Key Performance Indicators:
* Q2 2025 adjusted EPS: €1.23
* Q2 2025 group revenue: €10.7 billion
* TTM EPS (June 2025): -$0.97
* Legal provisions (Q2 2025): approximately €1.7 billion
Escalating Legal Liabilities Create Financial Strain
The company’s legal landscape continues to deteriorate, prompting S&P Global Ratings to revise Bayer AG’s outlook to negative on Thursday. The rating agency specifically cited increased risks from glyphosate and PCB litigation related to the Monsanto acquisition.
During the second quarter of 2025, Bayer recognized approximately €1.7 billion in litigation provisions and liabilities. This total included €1.2 billion allocated for glyphosate cases and an additional €530 million for PCB claims. These substantial legal reserves have profoundly impacted the company’s financial position.
Should investors sell immediately? Or is it worth buying Bayer PK?
S&P forecasts that litigation costs will reduce Bayer’s adjusted EBITDA for 2025 to €6.6 billion, representing a significant decline from the previous year’s €8.49 billion. As of June 30, 2025, the company had already set aside $7.4 billion for potential glyphosate liabilities. Approximately 4,400 Roundup cases remain pending, despite the company having already paid roughly $11 billion in settlements and faced over $8 billion in court awards.
Strategic Realignment Amid Uncertainty
In a cautiously optimistic move, Bayer has raised its full-year 2025 guidance, now anticipating currency-adjusted revenues between €46.0 and €48.0 billion. The company also increased its EPS forecast to a range of €4.80 to €5.30. This improved outlook remains tempered by expected significant currency effects and continuing outflows for litigation expenses.
Annual revenue growth for 2025 and 2026 is projected to remain below 1%, primarily driven by declining sales of top-performing drug Xarelto and regulatory pressures on certain crop protection products. The Crop Science division is expected to deliver stable yields—a critical factor for overall performance.
Concurrently, Bayer continues to advance its restructuring initiatives, having eliminated over 11,000 full-time positions since mid-2023. The company is increasingly focusing on pharmaceutical innovation with products such as Nubeqa and Kerendia, alongside agricultural advancements including the new herbicide Icafolin.
In a financially conservative measure, Bayer proposes reducing dividend payments by up to 95%. S&P anticipates annual dividend distributions of up to €150 million in both 2025 and 2026. The company’s next quarterly report is scheduled for November 10, 2025.
The critical question remains whether Bayer can regain financial strength. Current market performance largely depends on the company’s ability to contain litigation impacts and successfully execute its strategic turnaround. S&P’s negative outlook underscores concerns about free operating cash flow and Bayer’s capacity to sustainably deploy capital for growth. While the strong EPS improvement in Q2 offers a glimmer of hope, the billion-euro litigation provisions continue to cast long shadows over long-term financial stability.
Ad
Bayer PK Stock: Buy or Sell?! New Bayer PK Analysis from February 7 delivers the answer:
The latest Bayer PK figures speak for themselves: Urgent action needed for Bayer PK investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Bayer PK: Buy or sell? Read more here...
